Glioblastoma
Conditions
Interventions
High WASp activation group:None
Low WASp activation group:None
Sponsors
The First Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Postoperative histopathological confirmation of glioblastoma (WHO grade 4), IDH-wildtype (according to the 2021 WHO Classification of Tumours of the Central Nervous System); 2. No radiotherapy, chemotherapy, or immunotherapy prior to surgery; underwent gross total resection, followed by standard postoperative chemoradiotherapy; 3. Complete clinical data available (including imaging data and follow-up information); 4. Biospecimens stored in our hospital biobank, with sufficient tumor tissue reserved for subsequent staining and/or RNA extraction.
Exclusion criteria
Exclusion criteria: 1. Patients with concomitant other malignant tumors or severe autoimmune diseases (to exclude potential systemic immune effects on macrophages); 2. Recurrent glioma; 3. Patients who died from perioperative complications and therefore lacked valid follow-up data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Progression-free survival;Wiskott-Aldrich Syndrome protein (WASp);Phosphorylated Wiskott-Aldrich Syndrome protein (pWASp);Ionized calcium-binding adapter molecule 1(IBA1);SRY-related HMG-box 2 (SOX2); | — |
Secondary
| Measure | Time frame |
|---|---|
| Hematoxylin-eosin staining; | — |
Countries
China
Contacts
Public ContactYu Shi
The First Affiliated Hospital of the Army Medical University
Outcome results
None listed